Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in PLoS One Retrieve available abstracts of 241 articles: HTML format Text format

Single Articles

January 2018
1. CHEN WC, Su VY, Yu WK, Chen YW, et al
   Prognostic factors of noninvasive mechanical ventilation in lung cancer patients with acute respiratory failure.
   PLoS One. 2018;13:e0191204.
   PubMed     Text format     Abstract available
   
   
   
2. 
   Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
   PLoS One. 2018;13:e0191454.
   PubMed     Text format     Abstract available
   
   
   
3. CHUANG MC, Yang YH, Tsai YH, Hsieh MJ, et al
   Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study.
   PLoS One. 2018;13:e0191129.
   PubMed     Text format     Abstract available
   
   
   
4. BELQAID K, Tishelman C, Orrevall Y, Mansson-Brahme E, et al
   Dealing with taste and smell alterations-A qualitative interview study of people treated for lung cancer.
   PLoS One. 2018;13:e0191117.
   PubMed     Text format     Abstract available
   
   
   
5. PARK S, Ha S, Lee SH, Paeng JC, et al
   Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.
   PLoS One. 2018;13:e0189766.
   PubMed     Text format     Abstract available
   
   
   
6. SHIN DW, Chun S, Kim YI, Kim SJ, et al
   A national survey of lung cancer specialists' views on low-dose CT screening for lung cancer in Korea.
   PLoS One. 2018;13:e0192626.
   PubMed     Text format     Abstract available
   
   
   
7. KILVAER TK, Rakaee M, Hellevik T, Ostman A, et al
   Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
   PLoS One. 2018;13:e0192157.
   PubMed     Text format     Abstract available
   
   
   
8. KIRIU T, Yamamoto M, Nagano T, Hazama D, et al
   The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
   PLoS One. 2018;13:e0193018.
   PubMed     Text format     Abstract available
   
   
   
9. HOVANEC J, Siemiatycki J, Conway DI, Olsson A, et al
   Lung cancer and socioeconomic status in a pooled analysis of case-control studies.
   PLoS One. 2018;13:e0192999.
   PubMed     Text format     Abstract available
   
   
   
10. PAK K, Kim K, Kim MH, Eom JS, et al
    A decision tree model for predicting mediastinal lymph node metastasis in non-small cell lung cancer with F-18 FDG PET/CT.
    PLoS One. 2018;13:e0193403.
    PubMed     Text format     Abstract available
    
    
    
11. TAMIYA M, Tamiya A, Inoue T, Kimura M, et al
    Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
    PLoS One. 2018;13:e0192227.
    PubMed     Text format     Abstract available
    
    
    
12. 
    Correction: Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.
    PLoS One. 2018;13:e0194257.
    PubMed     Text format     Abstract available
    
    
    
13. CARVALHO S, Leijenaar RTH, Troost EGC, van Timmeren JE, et al
    18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
    PLoS One. 2018;13:e0192859.
    PubMed     Text format     Abstract available
    
    
    
14. MALEKI VAREKI S, Salim KY, Danter WR, Koropatnick J, et al
    Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
    PLoS One. 2018;13:e0191766.
    PubMed     Text format     Abstract available
    
    
    
15. HAN Y, Kim HJ, Kong KA, Kim SJ, et al
    Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191590.
    PubMed     Text format     Abstract available
    
    
    
16. ZHANG Z, Wang H, Ding Q, Xing Y, et al
    Establishment of patient-derived tumor spheroids for non-small cell lung cancer.
    PLoS One. 2018;13:e0194016.
    PubMed     Text format     Abstract available
    
    
    
17. MIHOUB M, Pichette A, Sylla B, Gauthier C, et al
    Bidesmosidic betulin saponin bearing L-rhamnopyranoside moieties induces apoptosis and inhibition of lung cancer cells growth in vitro and in vivo.
    PLoS One. 2018;13:e0193386.
    PubMed     Text format     Abstract available
    
    
    
18. BUHL IK, Santoni-Rugiu E, Ravn J, Hansen A, et al
    Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
    PLoS One. 2018;13:e0194609.
    PubMed     Text format     Abstract available
    
    
    
19. DEHUA Z, Mingming C, Jisheng W
    Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.
    PLoS One. 2018;13:e0193814.
    PubMed     Text format     Abstract available
    
    
    
20. CHANG WY, Wu YL, Su PL, Yang SC, et al
    The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.
    PLoS One. 2018;13:e0192161.
    PubMed     Text format     Abstract available
    
    
    
21. KIM CR, Kim EY, Kim YS, Ahn HK, et al
    Histologic subtypes are not associated with the presence of sarcopenia in lung cancer.
    PLoS One. 2018;13:e0194626.
    PubMed     Text format     Abstract available
    
    
    
22. CHEN CH, Chang CK, Tu CY, Liao WC, et al
    Radiomic features analysis in computed tomography images of lung nodule classification.
    PLoS One. 2018;13:e0192002.
    PubMed     Text format     Abstract available
    
    
    
23. FU M, Travier N, Martin-Sanchez JC, Martinez-Sanchez JM, et al
    Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    PLoS One. 2018;13:e0195441.
    PubMed     Text format     Abstract available
    
    
    
24. LEE EH, Park CH, Choi HJ, Kawala RA, et al
    Dexamethasone modified by gamma-irradiation as a novel anticancer drug in human non-small cell lung cancer.
    PLoS One. 2018;13:e0194341.
    PubMed     Text format     Abstract available
    
    
    
25. ERNST AK, Putscher A, Samatov TR, Suling A, et al
    Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy.
    PLoS One. 2018;13:e0192525.
    PubMed     Text format     Abstract available
    
    
    
26. LIU K, Zheng D, Xu G, Du Z, et al
    Correction: Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.
    PLoS One. 2018;13:e0196618.
    PubMed     Text format     Abstract available
    
    
    
27. BISAGNI A, Pagano M, Maramotti S, Zanelli F, et al
    Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
    PLoS One. 2018;13:e0196350.
    PubMed     Text format     Abstract available
    
    
    
28. CIRCU M, Cardelli J, Barr MP, O'Byrne K, et al
    Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
    PLoS One. 2018;13:e0197016.
    PubMed     Text format     Abstract available
    
    
    
29. DEROUEN MC, Hu L, McKinley M, Gali K, et al
    Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California.
    PLoS One. 2018;13:e0197146.
    PubMed     Text format     Abstract available
    
    
    
30. EDELSBERG J, Weycker D, Atwood M, Hamilton-Fairley G, et al
    Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
    PLoS One. 2018;13:e0197826.
    PubMed     Text format     Abstract available
    
    
    
31. KIM H, Kwon HJ, Park SY, Park Y, et al
    Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    PLoS One. 2018;13:e0198634.
    PubMed     Text format     Abstract available
    
    
    
32. ZHANG X, Nakajima T, Kim M, Yamaguchi A, et al
    Activatable fluorescence detection of epidermal growth factor receptor positive mediastinal lymph nodes in murine lung cancer model.
    PLoS One. 2018;13:e0198224.
    PubMed     Text format     Abstract available
    
    
    
33. WALTER RFH, Rozynek P, Casjens S, Werner R, et al
    Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    PLoS One. 2018;13:e0195716.
    PubMed     Text format     Abstract available
    
    
    
34. KIM KI, Jun JH, Baek H, Kim JH, et al
    Oral administration of herbal medicines for radiation pneumonitis in lung cancer patients: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0198015.
    PubMed     Text format     Abstract available
    
    
    
35. GU L, Wang Z, Zuo J, Li H, et al
    Prognostic significance of NF-kappaB expression in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2018;13:e0198223.
    PubMed     Text format     Abstract available
    
    
    
36. CHORNER PM, Moorehead RA
    A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.
    PLoS One. 2018;13:e0193344.
    PubMed     Text format     Abstract available
    
    
    
37. SILVA MA, Ryall KA, Wilm C, Caldara J, et al
    PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
    PLoS One. 2018;13:e0196464.
    PubMed     Text format     Abstract available
    
    
    
38. HSIEH LY, Chou FJ, Guo SE
    Information needs of patients with lung cancer from diagnosis until first treatment follow-up.
    PLoS One. 2018;13:e0199515.
    PubMed     Text format     Abstract available
    
    
    
39. DANISH L, Imig D, Allgower F, Scheurich P, et al
    Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.
    PLoS One. 2018;13:e0198203.
    PubMed     Text format     Abstract available
    
    
    
40. BLUME JD, D'Agostino McGowan L, Dupont WD, Greevy RA Jr, et al
    Second-generation p-values: Improved rigor, reproducibility, & transparency in statistical analyses.
    PLoS One. 2018;13:e0188299.
    PubMed     Text format     Abstract available
    
    
    
41. PLAGNOL V, Woodhouse S, Howarth K, Lensing S, et al
    Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
    PLoS One. 2018;13:e0193802.
    PubMed     Text format     Abstract available
    
    
    
42. YANG M, Feng Y, Yue C, Xu B, et al
    Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma.
    PLoS One. 2018;13:e0193428.
    PubMed     Text format     Abstract available
    
    
    
43. FERRARINI A, Forcato C, Buson G, Tononi P, et al
    A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
    PLoS One. 2018;13:e0193689.
    PubMed     Text format     Abstract available
    
    
    
44. ROTH JA, Carter-Harris L, Brandzel S, Buist DSM, et al
    A qualitative study exploring patient motivations for screening for lung cancer.
    PLoS One. 2018;13:e0196758.
    PubMed     Text format     Abstract available
    
    
    
45. HEIDEN BT, Chen G, Hermann M, Brown RKJ, et al
    18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer.
    PLoS One. 2018;13:e0199970.
    PubMed     Text format     Abstract available
    
    
    
46. LIM JU, Yeo CD, Kang HS, Park CK, et al
    Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.
    PLoS One. 2018;13:e0200341.
    PubMed     Text format     Abstract available
    
    
    
47. DUAN L, Ye L, Zhuang L, Zou X, et al
    VEGFC/VEGFR3 axis mediates TGFbeta1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cells.
    PLoS One. 2018;13:e0200452.
    PubMed     Text format     Abstract available
    
    
    
48. LU X, Gao J, Zhang Y, Zhao T, et al
    CTEN induces epithelial-mesenchymal transition (EMT) and metastasis in non small cell lung cancer cells.
    PLoS One. 2018;13:e0198823.
    PubMed     Text format     Abstract available
    
    
    
49. PANNUTI A, Filipovic A, Hicks C, Lefkowitz E, et al
    Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.
    PLoS One. 2018;13:e0194790.
    PubMed     Text format     Abstract available
    
    
    
50. YURCHENKO KS, Zhou P, Kovner AV, Zavjalov EL, et al
    Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.
    PLoS One. 2018;13:e0195425.
    PubMed     Text format     Abstract available
    
    
    
51. FATHI Z, Mousavi SAJ, Roudi R, Ghazi F, et al
    Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    PLoS One. 2018;13:e0200633.
    PubMed     Text format     Abstract available
    
    
    
52. ARMOIRY X, Tsertsvadze A, Connock M, Royle P, et al
    Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
    PLoS One. 2018;13:e0199575.
    PubMed     Text format     Abstract available
    
    
    
53. DUMENIL C, Massiani MA, Dumoulin J, Giraud V, et al
    Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
    PLoS One. 2018;13:e0195945.
    PubMed     Text format     Abstract available
    
    
    
54. NISHIO M, Nishizawa M, Sugiyama O, Kojima R, et al
    Computer-aided diagnosis of lung nodule using gradient tree boosting and Bayesian optimization.
    PLoS One. 2018;13:e0195875.
    PubMed     Text format     Abstract available
    
    
    
55. KU BM, Choi MK, Sun JM, Lee SH, et al
    Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
    PLoS One. 2018;13:e0194730.
    PubMed     Text format     Abstract available
    
    
    
56. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Text format     Abstract available
    
    
    
57. NISHIO M, Sugiyama O, Yakami M, Ueno S, et al
    Computer-aided diagnosis of lung nodule classification between benign nodule, primary lung cancer, and metastatic lung cancer at different image size using deep convolutional neural network with transfer learning.
    PLoS One. 2018;13:e0200721.
    PubMed     Text format     Abstract available
    
    
    
58. HIMES BE, Obraztsova K, Lian L, Shumyatcher M, et al
    Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
    PLoS One. 2018;13:e0197105.
    PubMed     Text format     Abstract available
    
    
    
59. PEIKERT T, Duan F, Rajagopalan S, Karwoski RA, et al
    Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening Trial.
    PLoS One. 2018;13:e0196910.
    PubMed     Text format     Abstract available
    
    
    
60. TARIQ H, Eldridge E, Welch I
    An efficient approach for feature construction of high-dimensional microarray data by random projections.
    PLoS One. 2018;13:e0196385.
    PubMed     Text format     Abstract available
    
    
    
61. FRICKE IB, De Souza R, Costa Ayub L, Francia G, et al
    Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
    PLoS One. 2018;13:e0196892.
    PubMed     Text format     Abstract available
    
    
    
62. JAFARINEZHAD A, YektaKooshali MH
    Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0202360.
    PubMed     Text format     Abstract available
    
    
    
63. CHEN X, Yang Y, Katz SI
    Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
    PLoS One. 2018;13:e0202384.
    PubMed     Text format     Abstract available
    
    
    
64. YANO Y, Kurebe H, Edahiro R, Hosono Y, et al
    Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    PLoS One. 2018;13:e0203070.
    PubMed     Text format     Abstract available
    
    
    
65. LEE DH, Tsao MS, Kambartel KO, Isobe H, et al
    Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    PLoS One. 2018;13:e0202865.
    PubMed     Text format     Abstract available
    
    
    
66. SCHAD F, Thronicke A, Steele ML, Merkle A, et al
    Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
    PLoS One. 2018;13:e0203058.
    PubMed     Text format     Abstract available
    
    
    
67. CONSONNI D, Carugno M, De Matteis S, Nordio F, et al
    Outdoor particulate matter (PM10) exposure and lung cancer risk in the EAGLE study.
    PLoS One. 2018;13:e0203539.
    PubMed     Text format     Abstract available
    
    
    
68. ZABLOCKA-SLOWINSKA K, Placzkowska S, Prescha A, Pawelczyk K, et al
    Systemic redox status in lung cancer patients is related to altered glucose metabolism.
    PLoS One. 2018;13:e0204173.
    PubMed     Text format     Abstract available
    
    
    
69. HUANG FF, Yang Q, Zhang J, Han XY, et al
    The structural equation model on self-efficacy during post-op rehabilitation among non-small cell lung cancer patients.
    PLoS One. 2018;13:e0204213.
    PubMed     Text format     Abstract available
    
    
    January 2017
70. RYUGE S, Sato Y, Nagashio R, Hiyoshi Y, et al
    Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers.
    PLoS One. 2017;12:e0173886.
    PubMed     Text format     Abstract available
    
    
    
71. HOU GX, Liu P, Yang J, Wen S, et al
    Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
    PLoS One. 2017;12:e0174515.
    PubMed     Text format     Abstract available
    
    
    
72. OGUMA T, Nagaoka T, Kurahashi M, Kobayashi N, et al
    Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer.
    PLoS One. 2017;12:e0174802.
    PubMed     Text format     Abstract available
    
    
    
73. FAN L, Chen L, Ni X, Guo S, et al
    Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population.
    PLoS One. 2017;12:e0175666.
    PubMed     Text format     Abstract available
    
    
    
74. DAVIES J, Patel M, Gridelli C, de Marinis F, et al
    Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.
    PLoS One. 2017;12:e0175679.
    PubMed     Text format     Abstract available
    
    
    
75. SHEN G, Lan Y, Zhang K, Ren P, et al
    Correction: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2017;12:e0176150.
    PubMed     Text format     Abstract available
    
    
    
76. HE M, Yang Z, Zhang L, Song C, et al
    Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.
    PLoS One. 2017;12:e0175466.
    PubMed     Text format     Abstract available
    
    
    
77. SHIRAI K, Kawashima M, Saitoh JI, Abe T, et al
    Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study.
    PLoS One. 2017;12:e0175589.
    PubMed     Text format     Abstract available
    
    
    
78. CAO G, Cheng D, Ye L, Pan Y, et al
    Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences.
    PLoS One. 2017;12:e0175284.
    PubMed     Text format     Abstract available
    
    
    
79. XU Z, Yan Y, Xiao L, Dai S, et al
    Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.
    PLoS One. 2017;12:e0175977.
    PubMed     Text format     Abstract available
    
    
    
80. INOUE Y, Shiihara J, Miyazawa H, Ohta H, et al
    A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.
    PLoS One. 2017;12:e0176525.
    PubMed     Text format     Abstract available
    
    
    
81. FUKUDA T, Nomura M, Kato Y, Tojo H, et al
    A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references.
    PLoS One. 2017;12:e0176219.
    PubMed     Text format     Abstract available
    
    
    
82. BAILEY G, Healy A, Young BD, Sharma E, et al
    Relative predictive value of lung cancer screening CT versus myocardial perfusion attenuation correction CT in the evaluation of coronary calcium.
    PLoS One. 2017;12:e0175678.
    PubMed     Text format     Abstract available
    
    
    
83. TAKAMOCHI K, Mogushi K, Kawaji H, Imashimizu K, et al
    Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    PLoS One. 2017;12:e0175622.
    PubMed     Text format     Abstract available
    
    
    
84. DENEKA AY, Haber L, Kopp MC, Gaponova AV, et al
    Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
    PLoS One. 2017;12:e0176747.
    PubMed     Text format     Abstract available
    
    
    
85. DURDA K, Kaklewski K, Gupta S, Szydlowski M, et al
    Serum folate concentration and the incidence of lung cancer.
    PLoS One. 2017;12:e0177441.
    PubMed     Text format     Abstract available
    
    
    
86. KIM JS, Cho MS, Nam JH, Kim HJ, et al
    Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer.
    PLoS One. 2017;12:e0177015.
    PubMed     Text format     Abstract available
    
    
    
87. JUN HY, Kim TH, Choi JW, Lee YH, et al
    Evaluation of connectivity map-discovered celastrol as a radiosensitizing agent in a murine lung carcinoma model: Feasibility study of diffusion-weighted magnetic resonance imaging.
    PLoS One. 2017;12:e0178204.
    PubMed     Text format     Abstract available
    
    
    
88. HOLMBOE S, Hansen PL, Thisgaard H, Block I, et al
    Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
    PLoS One. 2017;12:e0178286.
    PubMed     Text format     Abstract available
    
    
    
89. PARK SL, Murphy SE, Wilkens LR, Stram DO, et al
    Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort study.
    PLoS One. 2017;12:e0178435.
    PubMed     Text format     Abstract available
    
    
    
90. CAMERON SJS, Lewis KE, Huws SA, Hegarty MJ, et al
    A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer.
    PLoS One. 2017;12:e0177062.
    PubMed     Text format     Abstract available
    
    
    
91. CHANG HW, Lin ZM, Wu MJ, Wang LY, et al
    Characterization of a transgenic mouse model exhibiting spontaneous lung adenocarcinomas with a metastatic phenotype.
    PLoS One. 2017;12:e0175586.
    PubMed     Text format     Abstract available
    
    
    
92. CARRERAS-TORRES R, Johansson M, Haycock PC, Wade KH, et al
    Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study.
    PLoS One. 2017;12:e0177875.
    PubMed     Text format     Abstract available
    
    
    
93. CHANG YP, Chen YM, Lai CH, Lin CY, et al
    The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.
    PLoS One. 2017;12:e0178676.
    PubMed     Text format     Abstract available
    
    
    
94. WEISS GJ, Byron SA, Aldrich J, Sangal A, et al
    A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
    PLoS One. 2017;12:e0179170.
    PubMed     Text format     Abstract available
    
    
    
95. ABERNETHY AP, Arunachalam A, Burke T, McKay C, et al
    Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
    PLoS One. 2017;12:e0178420.
    PubMed     Text format     Abstract available
    
    
    
96. WU YT, Li X, Liu ZL, Xu Z, et al
    Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0179680.
    PubMed     Text format     Abstract available
    
    
    
97. YAGI S, Koh Y, Akamatsu H, Kanai K, et al
    Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.
    PLoS One. 2017;12:e0179744.
    PubMed     Text format     Abstract available
    
    
    
98. BEN-LULU S, Ziv T, Weisman-Shomer P, Benhar M, et al
    Correction: Nitrosothiol-Trapping-Based Proteomic Analysis of S-Nitrosylation in Human Lung Carcinoma Cells.
    PLoS One. 2017;12:e0179803.
    PubMed     Text format     Abstract available
    
    
    
99. SCHMIDT LH, Brand C, Stucke-Ring J, Schliemann C, et al
    Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
    PLoS One. 2017;12:e0177146.
    PubMed     Text format     Abstract available
    
    
    
100. LOISELLE JJ, Roy JG, Sutherland LC
     RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.
     PLoS One. 2017;12:e0180258.
     PubMed     Text format     Abstract available
     
     
     
101. DE MARCO C, Laudanna C, Rinaldo N, Oliveira DM, et al
     Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
     PLoS One. 2017;12:e0178865.
     PubMed     Text format     Abstract available
     
     
     
102. LEE AF, Chen MC, Chen CJ, Yang CJ, et al
     Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
     PLoS One. 2017;12:e0180383.
     PubMed     Text format     Abstract available
     
     
     
103. GUISIER F, Bohn P, Patout M, Piton N, et al
     In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.
     PLoS One. 2017;12:e0180576.
     PubMed     Text format     Abstract available
     
     
     
104. POWELL AC, Mirhadi AJ, Loy BA, Happe LE, et al
     Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer.
     PLoS One. 2017;12:e0181319.
     PubMed     Text format     Abstract available
     
     
     
105. GOTO A, Tanaka M, Yoshida M, Umakoshi M, et al
     The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.
     PLoS One. 2017;12:e0181270.
     PubMed     Text format     Abstract available
     
     
     
106. SAUSVILLE LN, Jones CC, Aldrich MC, Blot WJ, et al
     Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival.
     PLoS One. 2017;12:e0180471.
     PubMed     Text format     Abstract available
     
     
     
107. LIU PL, Liu WL, Chang JM, Chen YH, et al
     MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1.
     PLoS One. 2017;12:e0180844.
     PubMed     Text format     Abstract available
     
     
     
108. MESSARITAKIS I, Politaki E, Kotsakis A, Dermitzaki EK, et al
     Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
     PLoS One. 2017;12:e0181211.
     PubMed     Text format     Abstract available
     
     
     
109. SILVA EM, Mariano VS, Pastrez PRA, Pinto MC, et al
     High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.
     PLoS One. 2017;12:e0181125.
     PubMed     Text format     Abstract available
     
     
     
110. TANG ZM, Ling ZG, Wang CM, Wu YB, et al
     Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
     PLoS One. 2017;12:e0182117.
     PubMed     Text format     Abstract available
     
     
     
111. BANJARA M, Ghosh C, Dadas A, Mazzone P, et al
     Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.
     PLoS One. 2017;12:e0181409.
     PubMed     Text format     Abstract available
     
     
     
112. SARIN N, Engel F, Kalayda GV, Mannewitz M, et al
     Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
     PLoS One. 2017;12:e0181081.
     PubMed     Text format     Abstract available
     
     
     
113. PATNAIK SK, Kannisto ED, Mallick R, Vachani A, et al
     Whole blood microRNA expression may not be useful for screening non-small cell lung cancer.
     PLoS One. 2017;12:e0181926.
     PubMed     Text format     Abstract available
     
     
     
114. AL-SAAD S, Richardsen E, Kilvaer TK, Donnem T, et al
     The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
     PLoS One. 2017;12:e0181527.
     PubMed     Text format     Abstract available
     
     
     
115. OH TK, Jeon JH, Lee JM, Kim MS, et al
     Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery.
     PLoS One. 2017;12:e0181672.
     PubMed     Text format     Abstract available
     
     
     
116. KOLEK V, Grygarkova I, Koubkova L, Skrickova J, et al
     Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up.
     PLoS One. 2017;12:e0181803.
     PubMed     Text format     Abstract available
     
     
     
117. GONG X, Liu J, Zhang D, Yang D, et al
     GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
     PLoS One. 2017;12:e0182410.
     PubMed     Text format     Abstract available
     
     
     
118. LIU L, He Y, Ge G, Li L, et al
     Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.
     PLoS One. 2017;12:e0182168.
     PubMed     Text format     Abstract available
     
     
     
119. PELAEZ R, Morales X, Salvo E, Garasa S, et al
     beta3 integrin expression is required for invadopodia-mediated ECM degradation in lung carcinoma cells.
     PLoS One. 2017;12:e0181579.
     PubMed     Text format     Abstract available
     
     
     
120. MIRET M, Horvath-Puho E, Deruaz-Luyet A, Sorensen HT, et al
     Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study.
     PLoS One. 2017;12:e0181564.
     PubMed     Text format     Abstract available
     
     
     
121. TONG M, Wang J, Jiang N, Pan H, et al
     Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis.
     PLoS One. 2017;12:e0182282.
     PubMed     Text format     Abstract available
     
     
     
122. SCHMIDT LH, Brand C, Stucke-Ring J, Schliemann C, et al
     Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
     PLoS One. 2017;12:e0183201.
     PubMed     Text format     Abstract available
     
     
     
123. CHEN B, Yang L, Zhang R, Gan Y, et al
     Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients.
     PLoS One. 2017;12:e0182891.
     PubMed     Text format     Abstract available
     
     
     
124. CHENG CC, Chang J, Huang SC, Lin HC, et al
     YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.
     PLoS One. 2017;12:e0182149.
     PubMed     Text format     Abstract available
     
     
     
125. NAKANO T, Kanai Y, Amano Y, Yoshimoto T, et al
     Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures.
     PLoS One. 2017;12:e0181342.
     PubMed     Text format     Abstract available
     
     
     
126. PILYUGIN M, Descloux P, Andre PA, Laszlo V, et al
     BARD1 serum autoantibodies for the detection of lung cancer.
     PLoS One. 2017;12:e0182356.
     PubMed     Text format     Abstract available
     
     
     
127. KIM EK, Kim KA, Lee CY, Shim HS, et al
     The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
     PLoS One. 2017;12:e0171280.
     PubMed     Text format     Abstract available
     
     
     
128. WANICHTHANARAK K, Fan S, Grapov D, Barupal DK, et al
     Metabox: A Toolbox for Metabolomic Data Analysis, Interpretation and Integrative Exploration.
     PLoS One. 2017;12:e0171046.
     PubMed     Text format     Abstract available
     
     
     
129. ORTIZ-ZAPATER E, Lee RW, Owen W, Weitsman G, et al
     MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
     PLoS One. 2017;12:e0170798.
     PubMed     Text format     Abstract available
     
     
     
130. HARATI S, Cooper LA, Moran JD, Giuste FO, et al
     MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.
     PLoS One. 2017;12:e0170339.
     PubMed     Text format     Abstract available
     
     
     
131. FANG Y, Zhang C, Wu T, Wang Q, et al
     Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 Cells.
     PLoS One. 2017;12:e0170609.
     PubMed     Text format     Abstract available
     
     
     
132. NIKOLOVSKA K, Spillmann D, Haier J, Ladanyi A, et al
     Melanoma Cell Adhesion and Migration Is Modulated by the Uronyl 2-O Sulfotransferase.
     PLoS One. 2017;12:e0170054.
     PubMed     Text format     Abstract available
     
     
     
133. KISELEVA R, Greineder CF, Villa CH, Hood ED, et al
     Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1.
     PLoS One. 2017;12:e0169537.
     PubMed     Text format     Abstract available
     
     
     
134. ALSUBAIE N, Trahearn N, Raza SE, Snead D, et al
     Stain Deconvolution Using Statistical Analysis of Multi-Resolution Stain Colour Representation.
     PLoS One. 2017;12:e0169875.
     PubMed     Text format     Abstract available
     
     
     
135. CHOUAID C, Debieuvre D, Durand-Zaleski I, Fernandes J, et al
     Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).
     PLoS One. 2017;12:e0182798.
     PubMed     Text format     Abstract available
     
     
     
136. SHIN J, Song SY, Ahn HS, An BC, et al
     Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.
     PLoS One. 2017;12:e0183896.
     PubMed     Text format     Abstract available
     
     
     
137. JOVELET C, Madic J, Remon J, Honore A, et al
     Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.
     PLoS One. 2017;12:e0183319.
     PubMed     Text format     Abstract available
     
     
     
138. CHEN L, Lu J, Huang T, Cai YD, et al
     A computational method for the identification of candidate drugs for non-small cell lung cancer.
     PLoS One. 2017;12:e0183411.
     PubMed     Text format     Abstract available
     
     
     
139. YANG JH, Li XY, Wang X, Hou WJ, et al
     Long-term persistent infection of HPV 16 E6 up-regulate SP1 and hTERT by inhibiting LKB1 in lung cancer cells.
     PLoS One. 2017;12:e0182775.
     PubMed     Text format     Abstract available
     
     
     
140. KONG GM, Yu M, Gu Z, Chen Z, et al
     Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
     PLoS One. 2017;12:e0181601.
     PubMed     Text format     Abstract available
     
     
     
141. ZHANG C, Wei B, Li P, Yang K, et al
     Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
     PLoS One. 2017;12:e0173524.
     PubMed     Text format     Abstract available
     
     
     
142. WIEGERING A, Riegel J, Wagner J, Kunzmann V, et al
     The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases.
     PLoS One. 2017;12:e0173933.
     PubMed     Text format     Abstract available
     
     
     
143. ASOR E, Stav MY, Simon E, Fahoum I, et al
     Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.
     PLoS One. 2017;12:e0173760.
     PubMed     Text format     Abstract available
     
     
     
144. ECHTLER K, Konrad I, Lorenz M, Schneider S, et al
     Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis.
     PLoS One. 2017;12:e0172788.
     PubMed     Text format     Abstract available
     
     
     
145. PUNIA R, Raina K, Agarwal R, Singh RP, et al
     Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
     PLoS One. 2017;12:e0182870.
     PubMed     Text format     Abstract available
     
     
     
146. VAN DER WEKKEN AJ, Kuiper JL, Saber A, Terpstra MM, et al
     Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
     PLoS One. 2017;12:e0182885.
     PubMed     Text format     Abstract available
     
     
     
147. HSU MK, Lin HY, Chen FC
     NMD Classifier: A reliable and systematic classification tool for nonsense-mediated decay events.
     PLoS One. 2017;12:e0174798.
     PubMed     Text format     Abstract available
     
     
     
148. PARK JE, Chun SE, Reichel D, Min JS, et al
     Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
     PLoS One. 2017;12:e0173247.
     PubMed     Text format     Abstract available
     
     
     
149. JIN J, Hu K, Zhou Y, Li W, et al
     Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis.
     PLoS One. 2017;12:e0184412.
     PubMed     Text format     Abstract available
     
     
     
150. CAO X, MacNaughton P, Laurent JC, Allen JG, et al
     Radon-induced lung cancer deaths may be overestimated due to failure to account for confounding by exposure to diesel engine exhaust in BEIR VI miner studies.
     PLoS One. 2017;12:e0184298.
     PubMed     Text format     Abstract available
     
     
     
151. DE BIASE D, Genestreti G, Visani M, Acquaviva G, et al
     The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
     PLoS One. 2017;12:e0177822.
     PubMed     Text format     Abstract available
     
     
     
152. HSIEH CC, Sun YH, Lin SW, Yeh YC, et al
     Surgical outcomes of pulmonary mucoepidermoid carcinoma: A review of 41 cases.
     PLoS One. 2017;12:e0176918.
     PubMed     Text format     Abstract available
     
     
     
153. LEE DH, Hwang SH, Lim MK, Oh JK, et al
     Performance of urine cotinine and hypomethylation of AHRR and F2RL3 as biomarkers for smoking exposure in a population-based cohort.
     PLoS One. 2017;12:e0176783.
     PubMed     Text format     Abstract available
     
     
     
154. CAI G, Xiao F, Cheng C, Li Y, et al
     Population effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients.
     PLoS One. 2017;12:e0175850.
     PubMed     Text format     Abstract available
     
     
     
155. AGRAWAL V, Coroller TP, Hou Y, Lee SW, et al
     Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC.
     PLoS One. 2017;12:e0174268.
     PubMed     Text format     Abstract available
     
     
     
156. LYNCH CM, van Berkel VH, Frieboes HB
     Application of unsupervised analysis techniques to lung cancer patient data.
     PLoS One. 2017;12:e0184370.
     PubMed     Text format     Abstract available
     
     
     
157. CAI NL, Lau ATY, Yu FY, Wu DD, et al
     Purification and characterization of a highly specific polyclonal antibody against human extracellular signal-regulated kinase 8 and its detection in lung cancer.
     PLoS One. 2017;12:e0184755.
     PubMed     Text format     Abstract available
     
     
     
158. SHEN Z, Wang H, Xi W, Deng X, et al
     Multi-phase simultaneous segmentation of tumor in lung 4D-CT data with context information.
     PLoS One. 2017;12:e0178411.
     PubMed     Text format     Abstract available
     
     
     
159. KOO HJ, Kim MY, Koo JH, Sung YS, et al
     Computerized margin and texture analyses for differentiating bacterial pneumonia and invasive mucinous adenocarcinoma presenting as consolidation.
     PLoS One. 2017;12:e0177379.
     PubMed     Text format     Abstract available
     
     
     
160. ZHAO XK, Mao YM, Meng H, Song X, et al
     Shared susceptibility loci at 2q33 region for lung and esophageal cancers in high-incidence areas of esophageal cancer in northern China.
     PLoS One. 2017;12:e0177504.
     PubMed     Text format     Abstract available
     
     
     
161. FARQUHAR M, Penfold C, Benson J, Lovick R, et al
     Six key topics informal carers of patients with breathlessness in advanced disease want to learn about and why: MRC phase I study to inform an educational intervention.
     PLoS One. 2017;12:e0177081.
     PubMed     Text format     Abstract available
     
     
     
162. WANG XF, Zhu YT, Wang JJ, Zeng DX, et al
     The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients.
     PLoS One. 2017;12:e0185168.
     PubMed     Text format     Abstract available
     
     
     
163. ELLSWORTH SG, Rabatic BM, Chen J, Zhao J, et al
     Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy.
     PLoS One. 2017;12:e0183239.
     PubMed     Text format     Abstract available
     
     
     
164. WANG C, Zhang X, Li H, Li X, et al
     Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
     PLoS One. 2017;12:e0179664.
     PubMed     Text format     Abstract available
     
     
     
165. WANG L, Tang C, Xu B, Yang L, et al
     Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
     PLoS One. 2017;12:e0179000.
     PubMed     Text format     Abstract available
     
     
     
166. YIP SSF, Parmar C, Blezek D, Estepar RSJ, et al
     Application of the 3D slicer chest imaging platform segmentation algorithm for large lung nodule delineation.
     PLoS One. 2017;12:e0178944.
     PubMed     Text format     Abstract available
     
     
     
167. KEARNEY P, Hunsucker SW, Li XJ, Porter A, et al
     An integrated risk predictor for pulmonary nodules.
     PLoS One. 2017;12:e0177635.
     PubMed     Text format     Abstract available
     
     
     
168. KEE JY, Han YH, Kim DS, Mun JG, et al
     beta-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway.
     PLoS One. 2017;12:e0176937.
     PubMed     Text format     Abstract available
     
     
     
169. WANG T, Moon JY, Wu Y, Amos CI, et al
     Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium.
     PLoS One. 2017;12:e0185660.
     PubMed     Text format     Abstract available
     
     
     
170. SHAN S, She J, Xue ZQ, Su CX, et al
     Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies.
     PLoS One. 2017;12:e0185485.
     PubMed     Text format     Abstract available
     
     
     
171. WANG F, Xu X, Yang J, Min L, et al
     Height and lung cancer risk: A meta-analysis of observational studies.
     PLoS One. 2017;12:e0185316.
     PubMed     Text format     Abstract available
     
     
     
172. CIRCU M, Cardelli J, Barr M, O'Byrne K, et al
     Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
     PLoS One. 2017;12:e0184922.
     PubMed     Text format     Abstract available
     
     
     
173. NOWICKI-OSUCH K, Li Y, Challinor M, Gerrard DT, et al
     EINCR1 is an EGF inducible lincRNA overexpressed in lung adenocarcinomas.
     PLoS One. 2017;12:e0181902.
     PubMed     Text format     Abstract available
     
     
     
174. PIRIE-SHEPHERD SR, Painter C, Whalen P, Vizcarra P, et al
     Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients.
     PLoS One. 2017;12:e0179561.
     PubMed     Text format     Abstract available
     
     
     
175. TAKADA K, Okamoto T, Tominaga M, Teraishi K, et al
     Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.
     PLoS One. 2017;12:e0181598.
     PubMed     Text format     Abstract available
     
     
     
176. CHOI BH, Young HS, Quan YH, Rho J, et al
     Real-time computed tomography fluoroscopy-guided solitary lung tumor model in a rabbit.
     PLoS One. 2017;12:e0179220.
     PubMed     Text format     Abstract available
     
     
     
177. LENDECKEL D, Kromrey ML, Ittermann T, Schafer S, et al
     Pulmonary emphysema is a predictor of pneumothorax after CT-guided transthoracic pulmonary biopsies of pulmonary nodules.
     PLoS One. 2017;12:e0178078.
     PubMed     Text format     Abstract available
     
     
     
178. MINCHOM A, Thavasu P, Ahmad Z, Stewart A, et al
     A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
     PLoS One. 2017;12:e0186106.
     PubMed     Text format     Abstract available
     
     
     
179. ILIE M, Khambata-Ford S, Copie-Bergman C, Huang L, et al
     Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
     PLoS One. 2017;12:e0183023.
     PubMed     Text format     Abstract available
     
     
     
180. MUSCELLA A, Vetrugno C, Cossa LG, Antonaci G, et al
     Apoptosis by [Pt(O,O'-acac)(gamma-acac)(DMS)] requires PKC-delta mediated p53 activation in malignant pleural mesothelioma.
     PLoS One. 2017;12:e0181114.
     PubMed     Text format     Abstract available
     
     
     
181. YVOREL V, Patoir A, Casteillo F, Tissot C, et al
     PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
     PLoS One. 2017;12:e0180346.
     PubMed     Text format     Abstract available
     
     
     
182. BORIN TF, Shankar A, Angara K, Rashid MH, et al
     HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.
     PLoS One. 2017;12:e0178830.
     PubMed     Text format     Abstract available
     
     
     
183. KASPI E, Frankel D, Guinde J, Perrin S, et al
     Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor Performance status.
     PLoS One. 2017;12:e0183136.
     PubMed     Text format     Abstract available
     
     
     
184. KROSNICK JA, Malhotra N, Mo CH, Bruera EF, et al
     Perceptions of health risks of cigarette smoking: A new measure reveals widespread misunderstanding.
     PLoS One. 2017;12:e0182063.
     PubMed     Text format     Abstract available
     
     
     
185. TUDOR RA, D'Silva A, Tremblay A, MacEachern P, et al
     Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.
     PLoS One. 2017;12:e0181867.
     PubMed     Text format     Abstract available
     
     
     
186. JIN C, Zhang G, Zhang Y, Hua P, et al
     Isoalantolactone induces intrinsic apoptosis through p53 signaling pathway in human lung squamous carcinoma cells.
     PLoS One. 2017;12:e0181731.
     PubMed     Text format     Abstract available
     
     
     
187. YU PY, Gardner HL, Roberts R, Cam H, et al
     Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
     PLoS One. 2017;12:e0181885.
     PubMed     Text format     Abstract available
     
     
     
188. NAKAMURA S, Hayashi K, Imaoka Y, Kitamura Y, et al
     Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
     PLoS One. 2017;12:e0186192.
     PubMed     Text format     Abstract available
     
     
     
189. PEARCE A, Haas M, Viney R, Pearson SA, et al
     Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study.
     PLoS One. 2017;12:e0184360.
     PubMed     Text format     Abstract available
     
     
     
190. D'HOOGHE JNS, Goorsenberg AWM, de Bruin DM, Roelofs JJTH, et al
     Optical coherence tomography for identification and quantification of human airway wall layers.
     PLoS One. 2017;12:e0184145.
     PubMed     Text format     Abstract available
     
     
     
191. LIAO HF, Pan CH, Chou PY, Chen YF, et al
     Toxicological effects of NCKU-21, a phenanthrene derivative, on cell growth and migration of A549 and CL1-5 human lung adenocarcinoma cells.
     PLoS One. 2017;12:e0185021.
     PubMed     Text format     Abstract available
     
     
     
192. LAMBERT A, Jarlier M, Gourgou Bourgade S, Conroy T, et al
     Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
     PLoS One. 2017;12:e0183288.
     PubMed     Text format     Abstract available
     
     
     
193. SUTTON BC, Birse RT, Maggert K, Ray T, et al
     Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX(R) HS, a new highly sensitive assay for the MassARRAY(R) System.
     PLoS One. 2017;12:e0183715.
     PubMed     Text format     Abstract available
     
     
     
194. BUONOMO OC, Caredda E, Portarena I, Vanni G, et al
     New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
     PLoS One. 2017;12:e0184680.
     PubMed     Text format     Abstract available
     
     
     
195. HUANG JY, Wang R, Gao YT, Yuan JM, et al
     ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.
     PLoS One. 2017;12:e0184295.
     PubMed     Text format     Abstract available
     
     
     
196. KWIECIEN JM, Bassey-Archibong BI, Dabrowski W, Rayner LG, et al
     Loss of Kaiso expression in breast cancer cells prevents intra-vascular invasion in the lung and secondary metastasis.
     PLoS One. 2017;12:e0183883.
     PubMed     Text format     Abstract available
     
     
     
197. FORNARO L, Vivaldi C, Lin D, Xue H, et al
     Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
     PLoS One. 2017;12:e0182818.
     PubMed     Text format     Abstract available
     
     
     
198. LI Y, Xu H, Su S, Ye J, et al
     Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.
     PLoS One. 2017;12:e0183331.
     PubMed     Text format     Abstract available
     
     
     
199. KWAK KM, Paek D, Hwang SS, Ju YS, et al
     Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033.
     PLoS One. 2017;12:e0183404.
     PubMed     Text format     Abstract available
     
     
     
200. NOGUEIRA JORGE NA, Wajnberg G, Ferreira CG, de Sa Carvalho B, et al
     snoRNA and piRNA expression levels modified by tobacco use in women with lung adenocarcinoma.
     PLoS One. 2017;12:e0183410.
     PubMed     Text format     Abstract available
     
     
     
201. VANDEREYKEN M, Jacques S, Van Overmeire E, Amand M, et al
     Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner.
     PLoS One. 2017;12:e0185786.
     PubMed     Text format     Abstract available
     
     
     
202. MOON MH, Beck KS, Moon YK, Park JK, et al
     Incidence and clinical features of the incidentally found vascular stump thrombus during routine follow up after oncologic lung surgery.
     PLoS One. 2017;12:e0185140.
     PubMed     Text format     Abstract available
     
     
     
203. JIANG R, Dong X, Zhu W, Duan Q, et al
     Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers.
     PLoS One. 2017;12:e0184338.
     PubMed     Text format     Abstract available
     
     
     
204. KIND M, Klukowska-Rotzler J, Berezowska S, Arcaro A, et al
     Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.
     PLoS One. 2017;12:e0187308.
     PubMed     Text format     Abstract available
     
     
     
205. FORCELLA M, Oldani M, Epistolio S, Freguia S, et al
     Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
     PLoS One. 2017;12:e0187289.
     PubMed     Text format     Abstract available
     
     
     
206. SCHMIDT LH, Heitkotter B, Schulze AB, Schliemann C, et al
     Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
     PLoS One. 2017;12:e0186280.
     PubMed     Text format     Abstract available
     
     
     
207. OTOSHI T, Kataoka Y, Ikegaki S, Saito E, et al
     Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
     PLoS One. 2017;12:e0185850.
     PubMed     Text format     Abstract available
     
     
     
208. ZHAO J, Dinkel J, Warth A, Penzel R, et al
     CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation.
     PLoS One. 2017;12:e0182741.
     PubMed     Text format     Abstract available
     
     
     
209. LIU K, Zheng D, Xu G, Du Z, et al
     Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.
     PLoS One. 2017;12:e0187350.
     PubMed     Text format     Abstract available
     
     
     
210. ARNS A, Blessing M, Fleckenstein J, Stsepankou D, et al
     Phantom-based evaluation of dose exposure of ultrafast combined kV-MV-CBCT towards clinical implementation for IGRT of lung cancer.
     PLoS One. 2017;12:e0187710.
     PubMed     Text format     Abstract available
     
     
     
211. CHEN YF, Yuan A, Cho KH, Lu YC, et al
     Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
     PLoS One. 2017;12:e0187824.
     PubMed     Text format     Abstract available
     
     
     
212. JABS V, Edlund K, Konig H, Grinberg M, et al
     Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer.
     PLoS One. 2017;12:e0187246.
     PubMed     Text format     Abstract available
     
     
     
213. FRENZEL T, Hoffmann B, Schmitz R, Bethge A, et al
     Radiotherapy and chemotherapy change vessel tree geometry and metastatic spread in a small cell lung cancer xenograft mouse tumor model.
     PLoS One. 2017;12:e0187144.
     PubMed     Text format     Abstract available
     
     
     
214. SEO SR, Lee HM, Choi HS, Kim WT, et al
     Enhanced expression of cell-surface B-cell receptor-associated protein 31 contributes to poor survival of non-small cell lung carcinoma cells.
     PLoS One. 2017;12:e0188075.
     PubMed     Text format     Abstract available
     
     
     
215. SIKDAR S, Datta S, Datta S
     EAMA: Empirically adjusted meta-analysis for large-scale simultaneous hypothesis testing in genomic experiments.
     PLoS One. 2017;12:e0187287.
     PubMed     Text format     Abstract available
     
     
     
216. LIN CY, Wu YM, Hsieh MH, Wang CW, et al
     Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
     PLoS One. 2017;12:e0186567.
     PubMed     Text format     Abstract available
     
     
     
217. JIAO DM, Yan L, Wang LS, Hu HZ, et al
     Retraction: Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network.
     PLoS One. 2017;12:e0189070.
     PubMed     Text format    
     
     
     
218. LIU B, Zhao Y, Yuan J, Zeng L, et al
     Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
     PLoS One. 2017;12:e0187860.
     PubMed     Text format     Abstract available
     
     
     
219. VAN RIEL SJ, Ciompi F, Winkler Wille MM, Dirksen A, et al
     Malignancy risk estimation of pulmonary nodules in screening CTs: Comparison between a computer model and human observers.
     PLoS One. 2017;12:e0185032.
     PubMed     Text format     Abstract available
     
     
     
220. LI R, Zhang Y, Yuan Y, Lin Q, et al
     Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC.
     PLoS One. 2017;12:e0187390.
     PubMed     Text format     Abstract available
     
     
     
221. ZHOU S, Wang P, Su X, Chen J, et al
     High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
     PLoS One. 2017;12:e0187356.
     PubMed     Text format     Abstract available
     
     
     
222. MARCOS-VADILLO E, Garcia-Sanchez A, Sanz C, Davila I, et al
     PTGDR gene expression and response to dexamethasone treatment in an in vitro model.
     PLoS One. 2017;12:e0186957.
     PubMed     Text format     Abstract available
     
     
     
223. ISAKSSON S, Jonsson P, Monsef N, Brunnstrom H, et al
     CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma.
     PLoS One. 2017;12:e0186284.
     PubMed     Text format     Abstract available
     
     
     
224. BRINKHOF S, Groen HJM, Siesling SS, IJzerman MJ, et al
     Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.
     PLoS One. 2017;12:e0189251.
     PubMed     Text format     Abstract available
     
     
     
225. KIM ES, Baran AM, Mondo EL, Rodgers TD, et al
     Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
     PLoS One. 2017;12:e0189410.
     PubMed     Text format     Abstract available
     
     
     
226. ZHANG H, Diao H, Jia L, Yuan Y, et al
     Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.
     PLoS One. 2017;12:e0188960.
     PubMed     Text format     Abstract available
     
     
     
227. OOI CC, Mantalas GL, Koh W, Neff NF, et al
     High-throughput full-length single-cell mRNA-seq of rare cells.
     PLoS One. 2017;12:e0188510.
     PubMed     Text format     Abstract available
     
     
     
228. KANG G, Liu K, Hou B, Zhang N, et al
     3D multi-view convolutional neural networks for lung nodule classification.
     PLoS One. 2017;12:e0188290.
     PubMed     Text format     Abstract available
     
     
     
229. HAN KN, Kim HK, Choi YH
     Midterm outcomes of single port thoracoscopic surgery for major pulmonary resection.
     PLoS One. 2017;12:e0186857.
     PubMed     Text format     Abstract available
     
     
     
230. KIM H, Park CM, Keam B, Park SJ, et al
     The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.
     PLoS One. 2017;12:e0187500.
     PubMed     Text format     Abstract available
     
     
     
231. GALLARDO-ESTRELLA L, Pompe E, de Jong PA, Jacobs C, et al
     Normalized emphysema scores on low dose CT: Validation as an imaging biomarker for mortality.
     PLoS One. 2017;12:e0188902.
     PubMed     Text format     Abstract available
     
     
     
232. TAKAHASHI Y, Yasui T, Tamari K, Minami K, et al
     Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma.
     PLoS One. 2017;12:e0189697.
     PubMed     Text format     Abstract available
     
     
     
233. SABIR SH, Krishnamurthy S, Gupta S, Mills GB, et al
     Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing.
     PLoS One. 2017;12:e0189651.
     PubMed     Text format     Abstract available
     
     
     January 2016
234. GOK DURNALI A, Paksoy Turkoz F, Ardic Yukruk F, Tokluoglu S, et al
     Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups.
     PLoS One. 2016;11:e0152621.
     PubMed     Text format     Abstract available
     
     
     
235. ZHANG L, Qian H, Sha M, Luan Z, et al
     Downregulation of HOTAIR Expression Mediated Anti-Metastatic Effect of Artesunate on Cervical Cancer by Inhibiting COX-2 Expression.
     PLoS One. 2016;11:e0164838.
     PubMed     Text format     Abstract available
     
     
     
236. FORGACS A, Pall Jonsson H, Dahlbom M, Daver F, et al
     A Study on the Basic Criteria for Selecting Heterogeneity Parameters of F18-FDG PET Images.
     PLoS One. 2016;11:e0164113.
     PubMed     Text format     Abstract available
     
     
     
237. ZHANG L, Wang L, Tian P, Tian S, et al
     Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.
     PLoS One. 2016;11:e0165543.
     PubMed     Text format     Abstract available
     
     
     
238. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
     Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
     PLoS One. 2016;11:e0155262.
     PubMed     Text format     Abstract available
     
     
     
239. SCHUSTER C, Akslen LA, Straume O
     Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.
     PLoS One. 2016;11:e0155242.
     PubMed     Text format     Abstract available
     
     
     
240. SLADE RL, Pisaneschi F, Nguyen QD, Smith G, et al
     Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.
     PLoS One. 2016;11:e0161427.
     PubMed     Text format     Abstract available
     
     
     
241. WANG D, Zhang M, Gao X, Yu L, et al
     Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
     PLoS One. 2016;11:e0158307.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: